Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 10/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15514202 | 0.93 | FLT4 (0.47) | FLT4KDRDGAT1PTK2ALK | |
| SCHEMBL15514817 | 0.91 | PTK2 (0.48) | FLT4KDRPTK2ALK | |
| SCHEMBL15513597 | 0.91 | FLT4 (0.52) | FLT4KDRDGAT1PTK2KIT | |
| SCHEMBL15513392 | 0.89 | PTK2 (0.47) | FLT4KDRPTK2ALK | |
| SCHEMBL15514433 | 0.86 | FLT4 (0.52) | FLT4KDRDGAT1PTK2 | |
| SCHEMBL15514031 | 0.85 | FLT4 (0.42) | FLT4KDRPTK2 | |
| SCHEMBL15524337 | 0.85 | FLT4 (0.49) | FLT4KDRDGAT1PTK2ALK | |
| SCHEMBL15513821 | 0.85 | PTK2 (0.47) | FLT4KDRPTK2 | |
| SCHEMBL15524349 | 0.83 | FLT4 (0.52) | FLT4KDRPTK2KITFLT3 | |
| SCHEMBL15514780 | 0.83 | PTK2 (0.51) | FLT4KDRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885DGAT1 3345/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885DGAT1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.